Carotid Body Tumor - 25 Studies Found
| Terminated |
: Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma :
: 2009-05-29 |
| Completed |
: Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma :
: 2009-02-12 : Drug: Sunitinib 50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles) |
| Completed |
: First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma : Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) : 2011-06-09 :
|
| Active, not recruiting |
: Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation :
: 2014-06-04 : Other: PET-CT |
| Completed |
: Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma :
: 2007-04-09 : Drug: Ultratrace Iobenguane (MIBG) I 131 Phase I: Dose escalation protocol Phase II: Treatment schedule |
| Active, not recruiting |
: A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma :
: 2009-04-01 : Radiation: Ultratrace® Iobenguane I131 Each subject will be administered 3 mCi to 6 mCi Ultratrace& |
| Available |
: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma :
: 2016-11-08 : Drug: Ultratrace Iobenguane I131 Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 who |
| Active, not recruiting |
: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma :
: 2013-10-19 : Drug: Axitinib (AG-013736) Axitinib will be given as self-administered oral doses at the initial level o |
| Withdrawn |
: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma :
: 2013-09-10 :
|
| Not yet recruiting |
: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery :
|